In the News

207 News Items found
Memorial Sloan Kettering Alvin Goh, an expert in robotic surgery.
In the Clinic
MSK has expanded its bladder cancer surgery options with new robotic methods for constructing a substitute bladder.
Pattie Fuller smiles while wearing a pink plaid poncho
After immunotherapy and targeted therapy failed to bring a patient's melanoma under control, MSK doctors offered her a new treatment called tumor-infiltrating lymphocyte, or TIL, therapy.
(From left) David Scheinberg, Andrew Zelenetz, and Joseph Jurcic are using monoclonal antibodies to improve the treatment of patients with leukemia and lymphoma.
Therapies designed to target cancer while sparing healthy tissue show benefit, but have not yet reached full potential.
MSK's Wungki Park, MD, seen smiling in laboratory.
Learn how a novel drug is showing promise against lung and pancreatic cancer in early clinical trials by targeting the KRAS G12D mutation with a KRAS degrader.
Amy Speck
Feature
MSK surgeons have regularly used robotic surgery since 2007 to remove certain tumors in the chest and abdominal cavity. Now they are using robotic surgery to remove noncancerous tumors of the spine.
Zsofia Stadler presents at the ASCO meeting
Finding
Tumors with a biomarker called high microsatellite instability have been linked to inherited cancer mutations.
Andy Minn and Michael Glickman
Learn why immuno-oncology — which seeks to rally and strengthen the immune system’s ability to fight cancer — is the world’s next frontier in cancer research, and how MSK is overcoming some of the field's biggest challenges.
Learn how exercise can help many people live longer after they are diagnosed with cancer, according to a new study from MSK's Exercise-Oncology Service.
doctor and patients
In the Clinic
Discover how a watch-and-wait approach to treating rectal cancer can help people avoid surgery and preserve normal body functions.
Dr. Karuna Ganesh and Elizabeth Benitez in the lab.
Metastasis is responsible for about 9 of every 10 cancer deaths, and it remains one of the most daunting and least understood aspects of the disease. Researchers across MSK are approaching a wide variety of metastatic cancer types from many directions.